Recent News

• 12.08.2025 - Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes
• 11.10.2025 - Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
• 11.07.2025 - Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®
• 10.14.2025 - Assembly Biosciences Announces Upcoming Investor Conference Participation
• 10.10.2025 - Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe
• 09.29.2025 - Roy Buchanan
• 09.29.2025 - Roy Buchanan
• 08.25.2025 - Patrick Trucchio
• 08.25.2025 - Patrick Trucchio

Recent Filings

• 12.08.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 12.08.2025 - 8-K Current report
• 12.08.2025 - EX-99.1 EX-99.1
• 11.21.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 11.21.2025 - EFFECT Notice of Effectiveness
• 11.10.2025 - EX-99.1 EX-99.1
• 11.10.2025 - 8-K Current report
• 11.10.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.14.2025 - S-3 Registration statement under Securities Act of 1933
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities